← Back to Search

Patient portal message for Health Behaviors

N/A
Waitlist Available
Led By Amir Goren, PhD
Research Sponsored by Geisinger Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 2 weeks of the final message send date
Awards & highlights

Study Summary

As of November 2021, partly due to the COVID-19 pandemic, there has been a months-long national shortage of several types of blood in the U.S. (O-Pos, O-Neg, A-Neg, B-Neg, and AB-Neg), which has extended to a local blood shortage within the Geisinger community. The broad aim of this collaborative healthcare operations quality improvement project is to determine whether a message indicating that a patient's own blood type is in short supply increases the likelihood that they will donate, compared to a message that mentions a blood shortage without referencing the patient's blood type, or no message at all. Scientists in Geisinger's Behavioral Insights Team (BIT), part of Geisinger's Steele Institute for Health Innovation, will collaborate with Miller Keystone, where Geisinger refers patients who wish to donate blood and from whom Geisinger receives blood for clinical purposes. Patients with one of the needed blood types will be randomized to receive 1) a message about a blood shortage that does not specify the blood types in short supply or their own blood type (no-blood-type message), 2) the same message modified slightly to specify the recipient's blood type, and to mention that their blood type is in short supply (blood-type message), or 3) no message (shortage control group). A second no-contact control group of patients without any of the needed blood types will also be observed (no-shortage control group). Both the blood-type and no-blood-type messages are informed by behavioral science, emphasizing supply needs in local hospitals and providing community-relevant examples of why someone might need blood (e.g., farming or industrial accidents). The BIT will compare how many patients in each group choose to donate blood. They hypothesize that: 1) patients who receive either message will be more likely to donate than patients who receive no message; and 2) patients who receive the blood-type message will be more likely to donate than those who receive the no-blood-type message. With respect to the latter hypothesis, informing the recipient that they have one of the needed blood types may increase their perception that they are in a semi-unique position to help someone in need as compared to a more general message that may suffer from a diffusion of responsibility effect.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 2 weeks of the final message send date
This trial's timeline: 3 weeks for screening, Varies for treatment, and within 2 weeks of the final message send date for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants Who Attended a Donation Appointment
Secondary outcome measures
Number of Participants Who Scheduled a Blood Donation Appointment
Number of Participants Who Successfully Donated Blood

Trial Design

4Treatment groups
Experimental Treatment
Active Control
Group I: No-blood-type messageExperimental Treatment1 Intervention
This group will receive a message that does not mention the patient's blood type, or that the patient's blood type is in short supply.
Group II: Blood-type messageExperimental Treatment2 Interventions
This group will receive a message that mentions the patient's blood type and that states their blood type is in short supply.
Group III: Shortage controlActive Control1 Intervention
This group will not receive a message.
Group IV: No-shortage controlActive Control1 Intervention
This group will not receive a message.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Patient portal message
2021
N/A
~60700
Social responsibility
2023
N/A
~99580

Find a Location

Who is running the clinical trial?

Geisinger ClinicLead Sponsor
148 Previous Clinical Trials
1,827,000 Total Patients Enrolled
10 Trials studying Health Behaviors
653,625 Patients Enrolled for Health Behaviors
Amir Goren, PhDPrincipal InvestigatorGeisinger Clinic
20 Previous Clinical Trials
472,628 Total Patients Enrolled
4 Trials studying Health Behaviors
299,438 Patients Enrolled for Health Behaviors

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~17296 spots leftby Apr 2025